stockportfolio.pro
Stocks / CYTK vs ENSG
CYTK vs ENSG
Cytokinetics, Incorporated and The Ensign Group, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Cytokinetics, Incorporated (CYTK) | The Ensign Group, Inc. (ENSG) | |
|---|---|---|
| Market cap | $9.1B | $8.9B |
| Revenue (latest FY) | $88.04M | $5.06B |
| Net income (latest FY) | $-784.96M | $343.97M |
| Revenue growth (5y CAGR) | 9.5% | 16.1% |
| Net margin | -891.6% | 6.8% |
| Return on equity | 119.0% | 15.4% |
| P/E ratio | — | 24.6 |
| Dividend yield | — | 0.2% |
| Profitable years (of last 10) | 1 | 10 |
| Positive free cash flow | No | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CYTK — free Open ENSG — freeFrequently asked questions
Which is bigger, CYTK or ENSG?
Cytokinetics, Incorporated is larger by market capitalization — $9.1B versus $8.9B.
Which grows faster, CYTK or ENSG?
Over the last five fiscal years, The Ensign Group, Inc. grew revenue faster — 16.1%/yr versus 9.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.